---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-198322"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:44:32.306419+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics terminates ATM equity offering program; no shares sold

## Summary
- Effective Sept 8, 2025, terminated the ATM prospectus under the S-3 registration statement.
- Sales Agreement with Leerink and Cantor remains in effect but no sales without new filing.
- No shares of common stock were issued or sold under the program as of termination date.

## SEC filing metadata
- accession: 0001193125-25-198322
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312525198322/0001193125-25-198322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312525198322/d56083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-198322
- JSON: https://secwatch.observer/filing/0001193125-25-198322.json
- Plain text: https://secwatch.observer/filing/0001193125-25-198322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.